Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trypanosoma cruzi | 33 | 2022 | 149 | 5.300 |
Why?
|
| Chagas Disease | 19 | 2022 | 98 | 3.330 |
Why?
|
| Protozoan Proteins | 10 | 2020 | 182 | 1.320 |
Why?
|
| Trypanocidal Agents | 6 | 2019 | 39 | 1.200 |
Why?
|
| Oxadiazoles | 3 | 2015 | 15 | 1.060 |
Why?
|
| Imidazoles | 5 | 2018 | 126 | 0.910 |
Why?
|
| Cytochrome P-450 Enzyme System | 6 | 2015 | 92 | 0.800 |
Why?
|
| Thrombospondin 1 | 4 | 2022 | 23 | 0.760 |
Why?
|
| alpha-Defensins | 2 | 2013 | 17 | 0.760 |
Why?
|
| Drug Discovery | 2 | 2019 | 82 | 0.660 |
Why?
|
| Antiprotozoal Agents | 3 | 2018 | 30 | 0.620 |
Why?
|
| Coronary Vessels | 2 | 2010 | 85 | 0.590 |
Why?
|
| RNA Interference | 3 | 2010 | 243 | 0.580 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2010 | 86 | 0.570 |
Why?
|
| Animals | 34 | 2022 | 15081 | 0.560 |
Why?
|
| RNA, Small Interfering | 3 | 2021 | 409 | 0.550 |
Why?
|
| Epithelial Cells | 3 | 2018 | 384 | 0.550 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2015 | 7 | 0.520 |
Why?
|
| Benzamides | 2 | 2015 | 78 | 0.510 |
Why?
|
| Cocaine | 4 | 2020 | 232 | 0.510 |
Why?
|
| Enzyme Inhibitors | 4 | 2013 | 433 | 0.480 |
Why?
|
| Host-Parasite Interactions | 3 | 2009 | 42 | 0.460 |
Why?
|
| Flagella | 1 | 2013 | 29 | 0.450 |
Why?
|
| Laminin | 2 | 2006 | 61 | 0.450 |
Why?
|
| Locomotion | 1 | 2013 | 97 | 0.430 |
Why?
|
| Defensins | 1 | 2010 | 5 | 0.380 |
Why?
|
| Gene Regulatory Networks | 2 | 2016 | 120 | 0.370 |
Why?
|
| Humans | 37 | 2021 | 37093 | 0.370 |
Why?
|
| Receptors, Cell Surface | 2 | 2009 | 144 | 0.370 |
Why?
|
| Casein Kinase II | 2 | 2008 | 15 | 0.360 |
Why?
|
| Drug Design | 5 | 2018 | 162 | 0.360 |
Why?
|
| Mice | 16 | 2022 | 5913 | 0.360 |
Why?
|
| Trypanosoma brucei brucei | 4 | 2014 | 83 | 0.360 |
Why?
|
| MicroRNAs | 3 | 2020 | 426 | 0.350 |
Why?
|
| Mice, Inbred BALB C | 5 | 2015 | 661 | 0.320 |
Why?
|
| HIV-1 | 5 | 2020 | 706 | 0.320 |
Why?
|
| Endothelial Cells | 3 | 2022 | 308 | 0.320 |
Why?
|
| Aspergillus fumigatus | 2 | 2018 | 10 | 0.310 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 2 | 2014 | 8 | 0.310 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2019 | 168 | 0.300 |
Why?
|
| Ligands | 7 | 2021 | 349 | 0.300 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 92 | 0.290 |
Why?
|
| Galectin 3 | 2 | 2004 | 26 | 0.290 |
Why?
|
| Cloning, Molecular | 2 | 2012 | 325 | 0.290 |
Why?
|
| Myoblasts, Cardiac | 1 | 2006 | 4 | 0.280 |
Why?
|
| Trypanosomiasis | 2 | 2007 | 2 | 0.280 |
Why?
|
| Cell Membrane | 4 | 2013 | 381 | 0.270 |
Why?
|
| Antifungal Agents | 4 | 2018 | 148 | 0.270 |
Why?
|
| Antigens, Protozoan | 2 | 2006 | 72 | 0.260 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2017 | 77 | 0.260 |
Why?
|
| Gene Silencing | 1 | 2006 | 151 | 0.260 |
Why?
|
| Active Transport, Cell Nucleus | 3 | 2022 | 59 | 0.250 |
Why?
|
| Mucins | 2 | 2002 | 35 | 0.250 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2004 | 130 | 0.230 |
Why?
|
| 3' Untranslated Regions | 2 | 2020 | 74 | 0.220 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 1371 | 0.210 |
Why?
|
| Membrane Proteins | 1 | 2006 | 517 | 0.210 |
Why?
|
| Naegleria fowleri | 1 | 2021 | 2 | 0.210 |
Why?
|
| Cell Fusion | 1 | 2001 | 19 | 0.200 |
Why?
|
| Neuraminidase | 3 | 2008 | 9 | 0.200 |
Why?
|
| Myocardium | 2 | 2020 | 235 | 0.200 |
Why?
|
| beta Catenin | 1 | 2022 | 48 | 0.200 |
Why?
|
| Substrate Specificity | 6 | 2021 | 212 | 0.200 |
Why?
|
| Rats | 5 | 2022 | 3483 | 0.190 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2019 | 112 | 0.190 |
Why?
|
| Proline | 1 | 2021 | 43 | 0.190 |
Why?
|
| Myoblasts | 1 | 2020 | 27 | 0.180 |
Why?
|
| Antigens, Differentiation | 1 | 2000 | 25 | 0.180 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2021 | 65 | 0.180 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2020 | 19 | 0.180 |
Why?
|
| Glutamic Acid | 1 | 2021 | 128 | 0.180 |
Why?
|
| Myocytes, Cardiac | 3 | 2020 | 166 | 0.180 |
Why?
|
| Nucleus Accumbens | 1 | 2020 | 82 | 0.180 |
Why?
|
| Capsid | 1 | 2020 | 54 | 0.170 |
Why?
|
| Molecular Structure | 4 | 2015 | 492 | 0.170 |
Why?
|
| Candida albicans | 2 | 2018 | 164 | 0.170 |
Why?
|
| Homeostasis | 1 | 2021 | 188 | 0.170 |
Why?
|
| Triazoles | 4 | 2017 | 86 | 0.170 |
Why?
|
| Extracellular Matrix | 1 | 2000 | 115 | 0.170 |
Why?
|
| Nitroimidazoles | 1 | 2019 | 10 | 0.170 |
Why?
|
| Sterols | 4 | 2012 | 23 | 0.170 |
Why?
|
| Dipeptidases | 1 | 2019 | 9 | 0.170 |
Why?
|
| Tetrazoles | 2 | 2017 | 49 | 0.170 |
Why?
|
| Microvessels | 1 | 2019 | 28 | 0.170 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 290 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 70 | 0.160 |
Why?
|
| Virus Release | 2 | 2016 | 9 | 0.160 |
Why?
|
| Methamphetamine | 1 | 2021 | 159 | 0.160 |
Why?
|
| Pyridines | 2 | 2017 | 116 | 0.160 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 1015 | 0.160 |
Why?
|
| Colon | 1 | 2018 | 103 | 0.150 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 1 | 0.150 |
Why?
|
| Amino Acid Sequence | 3 | 2010 | 1180 | 0.150 |
Why?
|
| Protein Binding | 5 | 2017 | 972 | 0.150 |
Why?
|
| Phosphoproteins | 1 | 2018 | 163 | 0.150 |
Why?
|
| Cells, Cultured | 4 | 2018 | 1518 | 0.150 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 162 | 0.150 |
Why?
|
| Cell Adhesion | 3 | 2004 | 212 | 0.150 |
Why?
|
| Proteome | 1 | 2018 | 144 | 0.150 |
Why?
|
| Crystallography, X-Ray | 5 | 2018 | 265 | 0.140 |
Why?
|
| Protein Conformation | 5 | 2018 | 389 | 0.140 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2016 | 4 | 0.140 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2016 | 8 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2021 | 400 | 0.140 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2016 | 8 | 0.140 |
Why?
|
| Minority Groups | 1 | 2021 | 596 | 0.130 |
Why?
|
| Proline Oxidase | 1 | 2015 | 11 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2016 | 121 | 0.130 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 1568 | 0.130 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2015 | 55 | 0.130 |
Why?
|
| Models, Molecular | 5 | 2018 | 808 | 0.130 |
Why?
|
| Biotransformation | 1 | 2015 | 67 | 0.130 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 83 | 0.130 |
Why?
|
| Ergosterol | 1 | 2014 | 12 | 0.130 |
Why?
|
| Microsomes, Liver | 1 | 2015 | 70 | 0.130 |
Why?
|
| Tissue Distribution | 1 | 2015 | 207 | 0.120 |
Why?
|
| Carbamates | 1 | 2014 | 12 | 0.120 |
Why?
|
| Binding Sites | 3 | 2020 | 651 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2014 | 62 | 0.120 |
Why?
|
| Glycoproteins | 2 | 2008 | 106 | 0.120 |
Why?
|
| Autophagy | 1 | 2015 | 116 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2014 | 158 | 0.120 |
Why?
|
| Capsid Proteins | 1 | 2014 | 67 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 409 | 0.120 |
Why?
|
| HCT116 Cells | 1 | 2013 | 35 | 0.120 |
Why?
|
| Macrophages | 3 | 2003 | 439 | 0.110 |
Why?
|
| Molecular Weight | 2 | 2006 | 167 | 0.110 |
Why?
|
| Cocaine-Related Disorders | 1 | 2014 | 85 | 0.110 |
Why?
|
| HIV Infections | 2 | 2020 | 2303 | 0.110 |
Why?
|
| Adaptor Protein Complex 3 | 1 | 2012 | 1 | 0.110 |
Why?
|
| Adaptor Protein Complex delta Subunits | 1 | 2012 | 1 | 0.110 |
Why?
|
| Calreticulin | 1 | 2012 | 7 | 0.110 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 18 | 0.110 |
Why?
|
| Monocytes | 2 | 2019 | 257 | 0.110 |
Why?
|
| Hermanski-Pudlak Syndrome | 1 | 2012 | 13 | 0.110 |
Why?
|
| Neurons | 2 | 2021 | 1175 | 0.110 |
Why?
|
| Virus Assembly | 1 | 2012 | 41 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2013 | 224 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 325 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 259 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2015 | 513 | 0.100 |
Why?
|
| Hela Cells | 2 | 2016 | 366 | 0.100 |
Why?
|
| Signal Transduction | 4 | 2020 | 1908 | 0.100 |
Why?
|
| Mutation | 4 | 2020 | 1095 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 626 | 0.100 |
Why?
|
| Apoptosis | 2 | 2017 | 1398 | 0.090 |
Why?
|
| Trypanosomiasis, African | 1 | 2009 | 23 | 0.090 |
Why?
|
| Immunoprecipitation | 2 | 2012 | 131 | 0.090 |
Why?
|
| Brain | 1 | 2017 | 1346 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 484 | 0.090 |
Why?
|
| Indomethacin | 1 | 2009 | 28 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 290 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 306 | 0.080 |
Why?
|
| Phagocytosis | 1 | 1989 | 69 | 0.080 |
Why?
|
| Trypanosoma | 1 | 2008 | 8 | 0.080 |
Why?
|
| Fibronectins | 1 | 1989 | 66 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1369 | 0.080 |
Why?
|
| Amides | 1 | 2009 | 68 | 0.080 |
Why?
|
| Nuclear Localization Signals | 1 | 2008 | 17 | 0.080 |
Why?
|
| Serine Endopeptidases | 1 | 2008 | 38 | 0.080 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 59 | 0.080 |
Why?
|
| Female | 4 | 2015 | 20969 | 0.080 |
Why?
|
| Response Elements | 1 | 2008 | 56 | 0.080 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 34 | 0.080 |
Why?
|
| Vacuoles | 1 | 2007 | 25 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 172 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2007 | 87 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 578 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 2231 | 0.070 |
Why?
|
| Immunoblotting | 2 | 2010 | 176 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 146 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2007 | 143 | 0.070 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2008 | 77 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2008 | 366 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2012 | 272 | 0.070 |
Why?
|
| Epidermal Growth Factor | 2 | 2003 | 68 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2006 | 928 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 1609 | 0.070 |
Why?
|
| Virulence Factors | 1 | 2006 | 113 | 0.060 |
Why?
|
| Microsomes | 2 | 2018 | 52 | 0.060 |
Why?
|
| Catalytic Domain | 2 | 2018 | 109 | 0.060 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2003 | 22 | 0.060 |
Why?
|
| Transfection | 1 | 2004 | 523 | 0.060 |
Why?
|
| Methyltransferases | 2 | 2014 | 58 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 201 | 0.050 |
Why?
|
| Male | 5 | 2021 | 20025 | 0.050 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 7 | 0.050 |
Why?
|
| Hybridomas | 1 | 2002 | 29 | 0.050 |
Why?
|
| Endothelium | 1 | 2022 | 31 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2008 | 938 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2001 | 14 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2001 | 53 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 201 | 0.050 |
Why?
|
| Muscles | 1 | 2001 | 82 | 0.050 |
Why?
|
| Epitopes | 1 | 2002 | 148 | 0.050 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2021 | 17 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 53 | 0.050 |
Why?
|
| Cricetulus | 1 | 2021 | 80 | 0.050 |
Why?
|
| CHO Cells | 1 | 2021 | 124 | 0.050 |
Why?
|
| Cell Line | 1 | 2004 | 1354 | 0.050 |
Why?
|
| Acute Disease | 1 | 2021 | 147 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2020 | 60 | 0.050 |
Why?
|
| Communicable Diseases | 1 | 2021 | 45 | 0.050 |
Why?
|
| Lactose | 1 | 2000 | 14 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 51 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2000 | 52 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 448 | 0.050 |
Why?
|
| Heart | 1 | 2022 | 180 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2000 | 83 | 0.040 |
Why?
|
| Models, Animal | 1 | 2020 | 134 | 0.040 |
Why?
|
| Azoles | 2 | 2011 | 14 | 0.040 |
Why?
|
| Virus Integration | 1 | 2020 | 58 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 173 | 0.040 |
Why?
|
| Research Personnel | 1 | 2021 | 155 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2020 | 174 | 0.040 |
Why?
|
| Collagen | 1 | 2000 | 172 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2022 | 933 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 190 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1039 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2019 | 115 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 177 | 0.040 |
Why?
|
| Drug Stability | 1 | 2018 | 116 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 227 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 435 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 229 | 0.040 |
Why?
|
| Annexin A5 | 1 | 2017 | 26 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2000 | 859 | 0.040 |
Why?
|
| Ketoconazole | 1 | 2017 | 7 | 0.040 |
Why?
|
| Endocytosis | 2 | 2012 | 113 | 0.040 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2017 | 50 | 0.040 |
Why?
|
| Fluconazole | 1 | 2017 | 41 | 0.040 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2017 | 78 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 539 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2017 | 129 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2017 | 444 | 0.030 |
Why?
|
| Proteomics | 1 | 2018 | 325 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 477 | 0.030 |
Why?
|
| Heme | 1 | 2015 | 70 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 159 | 0.030 |
Why?
|
| Itraconazole | 1 | 2014 | 12 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 677 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 664 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2014 | 167 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 431 | 0.030 |
Why?
|
| Virion | 1 | 2014 | 69 | 0.030 |
Why?
|
| Cell Separation | 1 | 2014 | 93 | 0.030 |
Why?
|
| Cholesterol | 1 | 2014 | 205 | 0.030 |
Why?
|
| Tropical Medicine | 1 | 2012 | 7 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 461 | 0.030 |
Why?
|
| RNA | 1 | 2014 | 241 | 0.030 |
Why?
|
| Clathrin | 1 | 2012 | 21 | 0.030 |
Why?
|
| Life Cycle Stages | 1 | 2012 | 29 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 399 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2012 | 105 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 602 | 0.030 |
Why?
|
| Metabolome | 1 | 2012 | 53 | 0.030 |
Why?
|
| Mitochondria | 1 | 2015 | 487 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 601 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 174 | 0.020 |
Why?
|
| Neoplasms | 1 | 2021 | 1103 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 515 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2009 | 28 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2010 | 183 | 0.020 |
Why?
|
| Antiparasitic Agents | 1 | 2009 | 8 | 0.020 |
Why?
|
| Receptors, Fibronectin | 1 | 1989 | 3 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2009 | 35 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2009 | 35 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1989 | 116 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2012 | 453 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1989 | 61 | 0.020 |
Why?
|
| alpha Karyopherins | 1 | 2008 | 3 | 0.020 |
Why?
|
| beta Karyopherins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Hydroquinones | 1 | 2008 | 8 | 0.020 |
Why?
|
| K562 Cells | 1 | 2008 | 32 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 91 | 0.020 |
Why?
|
| Peptides | 1 | 2008 | 320 | 0.020 |
Why?
|
| Tyrosine | 1 | 2003 | 118 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 307 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 100 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 574 | 0.010 |
Why?
|